S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

RenovoRx Stock Forecast, Price & News

-0.06 (-1.46%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
47,111 shs
Average Volume
203,971 shs
Market Capitalization
$36.17 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RNXT News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RenovoRx logo

About RenovoRx

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$36.17 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.83 out of 5 stars

Medical Sector

801st out of 1,405 stocks

Pharmaceutical Preparations Industry

383rd out of 678 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

RenovoRx (NASDAQ:RNXT) Frequently Asked Questions

Is RenovoRx a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RenovoRx stock.
View analyst ratings for RenovoRx
or view top-rated stocks.

When is RenovoRx's next earnings date?

RenovoRx is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for RenovoRx

How were RenovoRx's earnings last quarter?

RenovoRx Inc (NASDAQ:RNXT) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02.
View RenovoRx's earnings history

What price target have analysts set for RNXT?

2 brokers have issued 12 month price objectives for RenovoRx's stock. Their forecasts range from $15.00 to $16.00. On average, they expect RenovoRx's share price to reach $15.50 in the next year. This suggests a possible upside of 281.8% from the stock's current price.
View analysts' price targets for RenovoRx
or view top-rated stocks among Wall Street analysts.

When did RenovoRx IPO?

(RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

What is RenovoRx's stock symbol?

RenovoRx trades on the NASDAQ under the ticker symbol "RNXT."

When does the company's lock-up period expire?

RenovoRx's lock-up period expires on Tuesday, February 22nd. RenovoRx had issued 1,850,000 shares in its IPO on August 26th. The total size of the offering was $16,650,000 based on an initial share price of $9.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

How do I buy shares of RenovoRx?

Shares of RNXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RenovoRx's stock price today?

One share of RNXT stock can currently be purchased for approximately $4.06.

How much money does RenovoRx make?

RenovoRx has a market capitalization of $36.17 million.

How many employees does RenovoRx have?

RenovoRx employs 2,021 workers across the globe.

What is RenovoRx's official website?

The official website for RenovoRx is www.renovorx.com.

Where are RenovoRx's headquarters?

How can I contact RenovoRx?

RenovoRx's mailing address is 333 W. SANTA CLARA STREET SUITE 900, SAN JOSE CA, 95110. The company can be reached via phone at 650-284-4433 or via fax at 650-397-4433.

This page was last updated on 1/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.